Abstract
Introduction
National Comprehensive Cancer Network (NCCN) guidelines recommend wide excision without axillary staging to treat phyllodes tumors of the breast. Without prospective trials to guide management, NCCN also recommends consideration of radiation therapy (XRT). We describe current patterns of care for the multidisciplinary management of phyllodes tumors.
Methods
Using Surveillance, Epidemiology, and End Results Program (SEER) data, we identified women diagnosed with phyllodes tumors between 2000 and 2012 who underwent surgical therapy. Trends in breast-conserving surgery (BCS), nodal sampling, and XRT were assessed using the Cochrane–Armitage test. Multivariable logistic regression was used to identify factors associated with treatment.
Results
Of 1238 patients, 56.9 % underwent BCS and 23.6 % underwent nodal sampling (10.5 % after BCS vs. 40.9 % after mastectomy). After surgery, 15.4 % received adjuvant XRT (BCS 12.9 %, and mastectomy 18.8 %). XRT utilization increased significantly over the study period (BCS, p = < 0.0001; mastectomy, p = 0.0003), while nodal sampling did not change significantly. Women were more likely to receive mastectomy if they were older or had larger tumors. Nodal sampling was also associated with older age, larger tumor size, and receipt of mastectomy. Receipt of XRT was associated with later year of diagnosis, larger tumors, and nodal assessment.
Conclusion
Over time, an increasing number of women received XRT after surgical management of phyllodes tumor, and one in four women underwent nodal sampling. While some of this practice can be attributed to concern about more advanced disease in the absence of strong data, there may be an educational gap regarding current guidelines and appropriate management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer. 1996;77:910–6.
Barth RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16(8):2288–94.
Lee AHS. Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast: spindle cell and fibroepithelial lesions. Histopathology. 2007;52(1):45–57.
Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71:3020–4.
Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J. 2001;77(909):428–35.
Salvadori B, Cusumano F, Del Bo R, et al. Surgical treatment of phyllodes tumors of the breast. Cancer. 1989;63:2532–6.
National Comprehensive Cancer Network. Phyllodes Tumor (Version 1.2016). Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 25 Jan 2016.
National Cancer Institute. Surveillance Epidemiology and End Results (SEER) program. Available at: http://seer.cancer.gov/about/overview. Accessed 1 Jan 2016.
Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–33.
Chaney AW, Pollack A, Mcneese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89(7):1502–11.
Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol. 2003;12:27–37.
Belkacémi Y, Bousquet G, Marsiglia H, et al. Phyllodes tumor of the breast. Int J Radiat Oncol. 2008;70(2):492–500.
Barrio AV, Clark BD, Goldberg JI, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14(10):2961–70.
Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998–2009. Ann Surg Oncol. 2014;21(4):1222–30.
Pilewskie M, Karsten M, Radosa J, Eaton A, King TA. Is sentinel lymph node biopsy indicated at completion mastectomy for ductal carcinoma in situ? Ann Surg Oncol. 2016;23(7):2229–34.
National Comprehensive Cancer Network. Invasive Breast Cancer (Version 1.2016). Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 25 Jan 2016.
Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83.
Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GP. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol. 2001;27(8):723–30.
Financial Support
Taiwo Adesoye receives support from the University of Wisconsin Surgical Oncology Research Training Program (T32 CA090217), and Heather B. Neuman is supported through the Building Interdisciplinary Research Careers in Women’s Health Scholar Program (NIH K12 HD055894).
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adesoye, T., Neuman, H.B., Wilke, L.G. et al. Current Trends in the Management of Phyllodes Tumors of the Breast. Ann Surg Oncol 23, 3199–3205 (2016). https://doi.org/10.1245/s10434-016-5314-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5314-0